Emergency Committee Holds Urgent Press Conference on March 10

Industry Faces Rising Costs Due to Oil Price and Exchange Rate Surges Amid Middle East Crisis

Concerns Over Shrinking R&D and Possible Suspension of Some Drug Approvals

"Jo

The 'Emergency Committee for the Reform of the Drug Pricing System for the Development of the Pharmaceutical and Bio Industry' (hereinafter referred to as the Emergency Committee), which includes the Korea Pharmaceutical and Bio-Pharma Manufacturers Association and the Korea Biomedicine Industry Association, officially demanded on March 10 that the government launch a joint public-private research initiative in response to the government's plan to lower drug prices. The Emergency Committee also stated that it could accept a reduction in the price of generic drugs from the current 53.55% to a level of 48.2%, which is a 10% reduction.


On the 10th, an emergency press conference of the Emergency Committee for Reforming the Pricing System for the Development of the Pharmaceutical and Bio Industry was held at the Korea Pharmaceutical and Bio-Pharma Manufacturers Association in Seocho-gu, Seoul. Photo by Minjae Kwak

On the 10th, an emergency press conference of the Emergency Committee for Reforming the Pricing System for the Development of the Pharmaceutical and Bio Industry was held at the Korea Pharmaceutical and Bio-Pharma Manufacturers Association in Seocho-gu, Seoul. Photo by Minjae Kwak

View original image

The Emergency Committee held an emergency press conference at the main auditorium on the 4th floor of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association in Seocho-gu, Seoul, and proposed that the government initiate a joint public-private study on three issues. The committee emphasized the need for a comprehensive analysis of the impact that the government's proposed drug price reduction and system reform could have on public health and the structure of the industry.


The Emergency Committee was established immediately after the government announced its drug price reduction plan at the end of November last year. This reform plan represents the first major revision of the drug pricing system in 13 years. If implemented, the reform, which focuses on lowering the prices of generic drugs, would require generics that are currently priced at 53–59% of the original drugs to reduce their prices to around 40%. The Emergency Committee has argued that a forced price cut would threaten public health and lead to job losses by discouraging investment in research and development and quality innovation, undermining the industrial foundation, and causing the discontinuation of essential medicines, and has called for the government to reconsider.


The committee presented three main requirements for the proposed joint research at the press conference: a multidimensional analysis of the impact of the drug price reform on public health and industrial structure; an investigation into the sharp increase in Contract Sales Organizations (CSOs), actual commission payments, and the development of system improvements to establish order in pharmaceutical distribution; and the formulation of advanced, sustainable industry strategies in line with the national goal of becoming one of the world's top five pharmaceutical and bio powerhouses.


As an additional rationale, the Emergency Committee pointed to the increased cost burden on the industry caused by recent surges in international oil prices and exchange rates resulting from the Middle East crisis. The committee stated, "Especially given the extremely high domestic dependence on imported active pharmaceutical ingredients, the burden on the industry will be even more severe due to this situation," and warned, "If large-scale, abrupt drug price cuts are enforced amid a highly unpredictable international environment, the industry will find it increasingly difficult to endure."


The Emergency Committee also plans to launch a petition campaign involving employees of member companies and pharmaceutical professionals. The committee urged the government to accept the industry's request for joint research, produce results within one year, and develop implementation measures together, emphasizing that this would enhance the transparency and predictability of policy decisions and improve acceptance within the industry.



The Emergency Committee also announced the maximum level of generic drug price reduction it is willing to accept. The price of generics subject to the reform is currently set at 53.55% of the original drug price, and the committee stated it could accept a reduction to 48.2%, which is a 10% decrease. Noh Yeonhong, Co-Chairman of the Emergency Committee and Chairman of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, said, "We can manage up to about 48.2%," but warned, "Any lower than that would place a burden on business management and the industrial base." Kwon Kibum, Chairman of Dongkook Pharmaceutical, added, "We are willing to make efforts to cut costs and share the burden with business partners to achieve a reduction of about 10%," but cautioned, "Excessive price cuts could seriously dampen investment activities and the overall industry atmosphere." However, the government has only indicated that it aims to lower the price to the 40% range and has not provided a specific figure.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing